The year ahead: 11 execs & experts predict what's in store for biopharma in 2016

With a record-setting year behind us, we can only imagine what’s ahead for the industry in the coming months. Fortunately, industry execs and experts from Sanofi, Boehringer, Bain, amfAR, Novocure, and others shared some of their own predictions with BioPharma Dive.

By Nicole Gray • Jan. 4, 2016

Bionor Pharma's 'kick and kill' HIV therapy shows promise

Bionor's therapy reduced the size of the latent HIV reservoir by an average of 40% across 17 patients. 

By Nicole Gray • Dec. 23, 2015

Explore the Trendline➔

Radiopharmaceuticals

A series of technological advances have led to an explosion of scientific progress — and dealmaking — involving medicines that can precisely deliver radioactive materials into tumors.   

By BioPharma Dive staff

11 biopharma execs & experts look back on 2015: A record year for record-breaking

We spoke with bigwigs from Sanofi, the Biosimilars Council, Novocure, Accenture, Bain, amfAR, Boehringer Ingelheim, and more on what they considered the most significant events that drove biopharma this past year.

By Nicole Gray • Dec. 22, 2015

UC Davis & Moffitt Cancer Center suspend KaloBios cancer trial after Shkreli debacle

Even through Martin Shkreli has been ousted as the biotech's CEO, the Moffitt Center wants no part in the clinical study. 

By Nicole Gray • Dec. 22, 2015

AstraZeneca's hopes for major cancer hopeful durvalumab dim

The firm's projected peak sales of $6.5 billion for the candidate now seem like they may be too optimistic.

By Nicole Gray • Dec. 21, 2015

UPDATED: House passes $1.1T spending bill with NIH boost, pediatric review voucher extension

The vote was 316 to 113.

By Sy Mukherjee • Dec. 18, 2015

Narcan is just the beginning: Unleashing the power of opioid antagonism

We spoke with Roger Crystal, CEO of Lightlake Therapeutics, about new ways to use old drugs to address opioid overdose and other addiction-related disorders.  

By Nicole Gray • Dec. 18, 2015

With eye on the future, AstraZeneca to beef up manufacturing, R&D presence in China

Investing directly in manufacturing and R&D capabilities in the country is seen as critical for future drug approvals in the market. 

By Nicole Gray • Dec. 17, 2015

Glaxo's IL-6 antibody shows promise in rheumatoid arthritis

GlaxoSmithKline is co-developing sirukumab with Janssen, with plans for a 2016 filing. 

By Nicole Gray • Dec. 17, 2015

Advaxis soars as FDA releases patient death-related clinical hold on its drugs

Shares have flown more than 55% since Tuesday afternoon.

By Nicole Gray • Dec. 17, 2015

Major research institutions fail transparency requirements, and pharma's not much better

Most academic scientists fail to disclose results to ClinicalTrials.gov on time, according to an investigation by Stat News.

By Nicole Gray • Dec. 15, 2015

In surprising setback for Merck, FDA panel refuses to back broader Zetia indication

The independent panel voted 10-5 against agreeing with Merck's claim that Vytorin, which combines Zetia and a statin, reduces heart attack and stroke risk.

By Nicole Gray • Dec. 15, 2015

New study: Antidepressants in pregnancy may be linked to autism

However, less than one percent of roughly 150,000 babies developed autism by age six or seven in the analysis. 

By Nicole Gray • Dec. 14, 2015

A lead researcher and a Boehringer SVP on the drumbeat of innovation in oral anticoagulants

We spoke with the two experts to better understand how innovation can thrive even when things seem to be headed south. 

By Nicole Gray • Dec. 11, 2015

21st Century Cures orphan drug exclusivity measures could divide consumer and patients advocates

Consumer advocate Public Citizen has released a report arguing the 21st Century Cures Act would drive biopharma profits at the expense of patients' access to medication. 

By Nicole Gray • Dec. 10, 2015

New analysis boosts Harvoni as 'safest' next-gen hep C option

In a postmarketing-based analysis, Harvoni was found to have fewer side effects than Sovaldi and VieKira Pak.

By Nicole Gray • Dec. 10, 2015

New study: Chemical castration doubles risk of Alzheimer's disease

Approximately 500,000 men with prostate cancer in the U.S. are taking anti-androgen medication, also know as chemical-castration drugs.

By Nicole Gray • Dec. 9, 2015

Obama FDA nominee under the microscope as regulators review pivotal Xarelto trial he ran

It could potentially prove to be a hurdle to Dr. Robert Califf's confirmation as FDA commissioner. 

By Nicole Gray • Dec. 8, 2015

Laguna Pharma calls it quits after phase 3 CVD drug flop

It's been less than a year since Laguna, headed up by CEO Bob Baltera, raised $30 million in venture financing. 

By Nicole Gray • Dec. 8, 2015

ASH15: Early-stage Keytruda trial shows unprecedented response in advanced multiple myeloma

In a phase 1 trial, Keytruda-treated patients with advanced multiple myeloma had an overall response rate (ORR) of 76%. 

By Nicole Gray • Dec. 8, 2015

Lilly's next-gen insulin hopes hit a buzzsaw as firm ditches late-stage diabetes candidate

The peglispro program is being shut down over concerns about severe liver toxicities. 

By Nicole Gray • Dec. 7, 2015

Merck's Keytruda gets presidential lift as Jimmy Carter announces he's cancer-free

Speaking at a Sunday school class at Maranatha Baptist Church in Georgia, the former president said there were no longer signs of cancer in his brain.

By Nicole Gray • Dec. 7, 2015

ASH15: J&J/AbbVie's Imbruvica cuts CLL death risk; Bluebird/Celgene buoyed by NIH myeloma data

New clinical data shows promise in patients with the hardest-to-treat cases of multiple myeloma and chronic lymphocytic leukemia (CLL). 

By Nicole Gray • Dec. 7, 2015

ASH15: Bluebird tanks 35% on gene therapy data; Novartis preps 2017 filing for blood cancer CAR-T

Biopharma firms chasing next-generation blood disorder therapies presented some major data at the American Society of Hematology meeting over the weekend.

By Nicole Gray • Dec. 7, 2015

Inside the bold new fight for an HIV cure: An exclusive interview with amfAR CEO Kevin Robert Frost

Seven years ago, Frost faced calls for his resignation over his suggestion that an HIV cure was an attainable goal. This week, his group announced the establishment of a research institute which he compares to NASA and the Manhattan Project that is 100% focused on this precise mission.

By Nicole Gray • Dec. 4, 2015